376 related articles for article (PubMed ID: 35602098)
1. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D; Lakshmi T
Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
[TBL] [Abstract][Full Text] [Related]
2. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.
Cui CX; Deng JN; Yan L; Liu YY; Fan JY; Mu HN; Sun HY; Wang YH; Han JY
J Ethnopharmacol; 2017 Aug; 208():24-35. PubMed ID: 28648927
[TBL] [Abstract][Full Text] [Related]
3. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
5. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.
Jin SH; Yang JH; Shin BY; Seo K; Shin SM; Cho IJ; Ki SH
Toxicol Appl Pharmacol; 2013 Aug; 271(1):95-105. PubMed ID: 23651738
[TBL] [Abstract][Full Text] [Related]
7. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
8. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H
Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291
[TBL] [Abstract][Full Text] [Related]
9. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
Xu K; Liu S; Zhao X; Zhang X; Fu X; Zhou Y; Xu K; Miao L; Li Z; Li Y; Qiao L; Bao J
Biomed Pharmacother; 2019 Feb; 110():844-849. PubMed ID: 30557833
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
11. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.
Vecchione G; Grasselli E; Voci A; Baldini F; Grattagliano I; Wang DQ; Portincasa P; Vergani L
World J Gastroenterol; 2016 Jul; 22(26):6016-26. PubMed ID: 27468193
[TBL] [Abstract][Full Text] [Related]
12. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Ou Q; Weng Y; Wang S; Zhao Y; Zhang F; Zhou J; Wu X
Dig Dis Sci; 2018 Dec; 63(12):3398-3408. PubMed ID: 30191499
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
Li L; Hai J; Li Z; Zhang Y; Peng H; Li K; Weng X
Food Chem Toxicol; 2014 Jan; 63():166-73. PubMed ID: 23978414
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms.
Hamouda AO; Abdel-Hamed AR; Abo-Elmatty DM; Khedr NF; Ghattas MH
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8644-8659. PubMed ID: 36524484
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
17. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription.
Che Y; Shi X; Zhong X; Zhang Y; Si R; Li Y; Shi Y
J Nutr Biochem; 2020 Aug; 82():108400. PubMed ID: 32438122
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the role of cadmium, lead, arsenic, and mercury in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Tinkov AA; Aschner M; Santamaria A; Bogdanov AR; Tizabi Y; Virgolini MB; Zhou JC; Skalny AV
Environ Res; 2023 Dec; 238(Pt 1):117134. PubMed ID: 37714366
[TBL] [Abstract][Full Text] [Related]
20. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
